Pulmonary Hypertension: WHO Classification, Diagnosis, and Targeted Therapy

Pulmonary hypertension (PH) is defined as a resting mean pulmonary arterial pressure (mPAP) ≥20 mmHg measured by right heart catheterization (RHC), reduced from the previous threshold of 25 mmHg in 2018. This hemodynamic definition is further classified based on pulmonary vascular resistance (PVR) and pulmonary arterial wedge pressure (PAWP).

Hemodynamic Classifications:

⚡ HIGH-YIELD: Pre-capillary PH primarily affects the pulmonary arterioles and is characteristic of WHO Groups 1, 3, 4, and some Group 5 conditions. Post-capillary PH results from elevated left-sided filling pressures (WHO Group 2). Combined pre- and post-capillary PH represents advanced left heart disease with secondary pulmonary vascular remodeling.

🔬 DIAGNOSIS: Right heart catheterization remains the gold standard for confirming PH diagnosis and determining hemodynamic phenotype. Echocardiographic estimation using tricuspid regurgitation velocity (TRV) provides screening but cannot definitively diagnose PH. A TRV >2.8 m/s (corresponding to RVSP >31 mmHg) warrants further evaluation.

⚠️ PEARL: The 2018 hemodynamic definition change means that patients with mPAP 20-24 mmHg now meet criteria for PH, though the clinical significance in this borderline range remains under investigation. Exercise testing may reveal abnormal hemodynamics in symptomatic patients with borderline resting pressures.

The World Health Organization (WHO) classification system organizes PH into five distinct groups based on similar pathophysiology, clinical presentation, and therapeutic approach. Understanding this classification is crucial for appropriate diagnostic workup and treatment selection.

WHO Group 1 - Pulmonary Arterial Hypertension (PAH):

• Idiopathic PAH (IPAH): No identifiable cause
• Heritable PAH: BMPR2, ALK1, ENG, SMAD9, CAV1, KCNK3 mutations
• Drug/toxin-induced: Appetite suppressants, dasatinib, interferon
• Associated PAH (APAH): Connective tissue disease, congenital heart disease, portal hypertension, HIV, schistosomiasis
• Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH)

WHO Group 2 - PH due to Left Heart Disease:

• Heart failure with preserved ejection fraction (HFpEF)
• Heart failure with reduced ejection fraction (HFrEF)
• Valvular disease (mitral stenosis, mitral regurgitation, aortic stenosis)
• Congenital/acquired left heart inflow/outflow obstruction

WHO Group 3 - PH due to Lung Disease/Hypoxia:

• Chronic obstructive pulmonary disease (COPD)
• Interstitial lung disease (ILD)
• Sleep-disordered breathing
• Alveolar hypoventilation disorders
• Chronic high-altitude exposure

WHO Group 4 - Chronic Thromboembolic PH (CTEPH):

• Chronic thromboembolic disease with organized thrombi
• Pulmonary artery sarcoma, arteritis, congenital stenosis

WHO Group 5 - PH with Unclear/Multifactorial Mechanisms:

• Hematologic disorders (myeloproliferative disorders, splenectomy)
• Systemic disorders (sarcoidosis, neurofibromatosis, glycogen storage disease)
• Metabolic disorders (thyroid disorders, Gaucher disease)
• Chronic kidney disease

⚡ HIGH-YIELD: Group 2 PH is the most common form, representing >50% of all PH cases. Group 1 PAH, while less common, has the most established targeted therapies and best-characterized pathophysiology.

The diagnostic evaluation of suspected PH requires a systematic approach to confirm the diagnosis, determine the underlying cause, and assess disease severity. The process involves multiple imaging modalities, laboratory tests, and ultimately hemodynamic assessment.

Diagnostic Algorithm for Pulmonary Hypertension

Clinical Suspicion (dyspnea, fatigue, syncope, chest pain) ↓ Echocardiography (TRV, RVSP estimation) ↓ TRV ≤2.8 m/s → Low probability PH TRV 2.9-3.4 m/s → Intermediate probability TRV >3.4 m/s → High probability PH ↓ Further evaluation: • Chest CT (HRCT if ILD suspected) • Pulmonary function tests • VQ scan (exclude CTEPH) • Laboratory workup • 6-minute walk test ↓ Right Heart Catheterization (if high suspicion persists) ↓ mPAP ≥20 mmHg? ↓ Determine WHO Group Based on hemodynamics

Essential Diagnostic Tests:

Laboratory Workup:

• Complete blood count, comprehensive metabolic panel
• Brain natriuretic peptide (BNP) or NT-proBNP
• Thyroid function tests
• HIV serology, hepatitis panel
• Antinuclear antibody (ANA), anti-Scl-70, anti-centromere
• Complement levels (C3, C4) if CTD suspected

Imaging Studies:

• Chest X-ray: Enlarged PA, RV enlargement, pruning of peripheral vessels
• CT chest: High-resolution CT for ILD, CT-PA if acute PE suspected
• Ventilation-perfusion (VQ) scan: Essential to exclude CTEPH; more sensitive than CT-PA for chronic disease
• Cardiac MRI: Gold standard for RV assessment, useful for prognosis

Functional Assessment:

• 6-minute walk distance (6MWD): Important prognostic marker; normal >440m
• Cardiopulmonary exercise testing: Peak VO₂, VE/VCO₂ slope
• WHO Functional Class: I (asymptomatic) to IV (symptoms at rest)

⚠️ PEARL: VQ scan should be performed in all newly diagnosed PH patients to exclude CTEPH, as this represents the only potentially curable form of PH through pulmonary endarterectomy or balloon pulmonary angioplasty.

Targeted PAH therapy focuses on three main pathways: prostacyclin, endothelin, and nitric oxide signaling. Modern treatment approaches emphasize early combination therapy and risk stratification to optimize outcomes.

Prostacyclin Pathway Agents:

Endothelin Receptor Antagonists (ERAs):

• Bosentan: Dual ERA, hepatotoxicity monitoring required
• Ambrisentan: Selective ERA, lower hepatotoxicity risk
• Macitentan: Dual ERA, improved tissue penetration

Phosphodiesterase-5 Inhibitors (PDE5i):

• Sildenafil: 20mg TID, most studied
• Tadalafil: 40mg daily, longer half-life

Risk Stratification and Treatment Goals:

Risk Assessment Parameters:

Low Risk (<5% 1-year mortality): • WHO FC I-II • 6MWD >440m • BNP <50 ng/L or NT-proBNP <300 ng/L • Echo: No pericardial effusion • Hemodynamics: RAP <8 mmHg, CI ≥2.5 L/min/m²

High Risk (>10% 1-year mortality): • WHO FC IV • 6MWD <165m • BNP >300 ng/L or NT-proBNP >1400 ng/L • Echo: Pericardial effusion • Hemodynamics: RAP >15 mmHg, CI <2.0 L/min/m²

Treatment Algorithm:

• Low-intermediate risk: Start dual combination therapy (ERA + PDE5i)
• High risk: Consider initial triple therapy including prostacyclin
• Treatment goals: Achieve low-risk status markers

⚡ HIGH-YIELD: The AMBITION trial demonstrated superior outcomes with initial combination therapy (ambrisentan + tadalafil) compared to monotherapy, establishing combination as first-line treatment.

🔑 KEY CONCEPT: Calcium channel blockers should only be used in the small subset of IPAH patients (<10%) who demonstrate acute vasoreactivity during RHC (decrease in mPAP ≥10 mmHg to absolute value <40 mmHg with increased or unchanged cardiac output).

Advanced therapies are reserved for patients with severe PAH who remain symptomatic despite optimal medical therapy, and interventional procedures are specific to certain PH etiologies.

Prostacyclin Therapy: Parenteral prostacyclins remain the most potent PAH therapies but require specialized delivery systems and careful monitoring.

Intravenous Prostacyclins:

• Epoprostenol: Gold standard, requires central venous access and continuous cold-chain delivery
• Treprostinil: Room-stable alternative, can be given IV or SubQ
• Starting dose: Epoprostenol 2 ng/kg/min, uptitrated by 2 ng/kg/min every 15 minutes during initiation

Subcutaneous and Inhaled Options:

• Subcutaneous treprostinil: Avoids central line complications but causes significant site pain
• Inhaled treprostinil: 4 breaths QID, can be added to oral combination therapy
• Inhaled iloprost: 6-9 times daily, shorter half-life requires frequent dosing

Balloon Atrial Septostomy (BAS): Palliative procedure creating right-to-left shunt to decompress RV in severe PAH:

• Indications: Refractory WHO FC IV symptoms, recurrent syncope
• Contraindications: PAWP >15 mmHg, PVR >55 Wood Units, O₂ saturation <85%
• Mechanism: Reduces RV preload at expense of systemic hypoxemia

Lung Transplantation:

CTEPH-Specific Interventions:

Pulmonary Endarterectomy (PEA):

• Gold standard for operable CTEPH
• Criteria: Surgically accessible disease (main, lobar, segmental PA)
• Contraindications: PVR <300 dynes·s·cm⁻⁵, significant comorbidities
• Outcomes: Excellent long-term survival when successful

Balloon Pulmonary Angioplasty (BPA):

• Alternative for inoperable CTEPH or residual PH post-PEA
• Technique: Serial sessions targeting segmental/subsegmental arteries
• Complications: Pulmonary edema, vessel rupture
• Results: Gradual improvement in hemodynamics and functional capacity

⚠️ PEARL: CTEPH patients should be evaluated at experienced centers with both cardiac surgery and interventional capabilities. Even 'inoperable' disease may be amenable to PEA with advances in surgical techniques.

💊 TREATMENT: Riociguat (sGC stimulator) is specifically approved for inoperable CTEPH and represents the only targeted therapy with proven efficacy in this population.

Prognosis in pulmonary hypertension varies significantly by WHO group and individual risk factors. Contemporary risk stratification tools guide treatment intensity and timing of advanced interventions.

Prognostic Indicators:

Clinical Parameters:

• WHO Functional Class: Strong predictor of survival
  • FC I-II: >95% 1-year survival
  • FC III: 85-90% 1-year survival
  • FC IV: 65-70% 1-year survival
• 6-minute walk distance: Each 50m decrease associated with 7% increased mortality risk
• Syncope: Indicates severe disease, poor prognosis

Biomarkers:

• BNP/NT-proBNP: Most validated biomarker
  • BNP <50 ng/L: Low risk
  • BNP 50-300 ng/L: Intermediate risk
  • BNP >300 ng/L: High risk
• Troponin elevation: Indicates RV strain, poor prognosis
• Uric acid >7.0 mg/dL: Associated with increased mortality

Imaging Markers:

• Pericardial effusion: Sign of advanced RV failure
• RV/LV ratio >1.0: Severe RV enlargement
• Tricuspid annular plane systolic excursion (TAPSE) <1.8 cm: RV dysfunction
• RV fractional area change <35%: Impaired RV function

Hemodynamic Prognostic Factors:

| Parameter | Low Risk | Intermediate Risk | High Risk | |-----------|----------|-------------------|-----------|| | RAP | <8 mmHg | 8-14 mmHg | >14 mmHg | | Cardiac Index | >2.5 L/min/m² | 2.0-2.4 L/min/m² | <2.0 L/min/m² | | Mixed venous O₂ saturation | >65% | 60-65% | <60% |

Risk Calculators:

REVEAL Risk Score: Validated tool incorporating:

• Demographics (age, sex)
• Comorbidities (renal insufficiency, connective tissue disease)
• Vital signs (heart rate, systolic BP)
• Functional assessment (6MWD, WHO FC)
• Laboratory values (BNP, creatinine)
• Hemodynamics (RAP, PVR)

French Pulmonary Hypertension Network Equation: Simpler tool using three variables:

• WHO functional class
• 6-minute walk distance
• RAP from RHC

Treatment Response Assessment:

Follow-up Schedule:

Baseline Assessment → 3-4 months → 6 months → Every 6-12 months

At Each Visit: • WHO functional class • 6-minute walk test • BNP or NT-proBNP • Echocardiography • Consider repeat RHC if:

• Clinical deterioration
• Considering advanced therapy
• Inadequate response to treatment

🔑 KEY CONCEPT: Modern PAH management emphasizes achieving and maintaining low-risk status. Patients not achieving low-risk criteria within 3-4 months of treatment initiation should have therapy escalated.

⚠️ PEARL: Rapid progression (diagnosis to death <2 years) occurs in ~20% of PAH patients and is associated with younger age, higher PVR, and certain genetic mutations (BMPR2, EIF2AK4).

Certain patient populations require specialized approaches due to unique pathophysiology, treatment considerations, or pregnancy-related risks.

Connective Tissue Disease-Associated PAH (CTD-PAH): Represents the largest subgroup of associated PAH, with distinct characteristics:

Systemic Sclerosis (SSc-PAH):

• Prevalence: 8-12% of SSc patients develop PAH
• Screening: Annual echocardiography + PFTs recommended
• DETECT algorithm: Uses clinical variables to identify high-risk patients
• Prognosis: Worse than IPAH, median survival 3-5 years
• Treatment response: Often requires combination therapy earlier

Lupus-Associated PAH:

• Prevalence: 0.5-4% of SLE patients
• Association: Antiphospholipid antibodies, Raynaud's phenomenon
• Treatment: Standard PAH therapy, immunosuppression may help

Congenital Heart Disease-Associated PAH (CHD-PAH):

Eisenmenger Syndrome:

• Definition: Reversal of left-to-right shunt due to severe PAH
• Management: Avoid systemic vasodilators, maintain systemic SVR
• Specific considerations:
  • Phlebotomy only if symptoms + hematocrit >65%
  • Iron deficiency common and should be treated
  • Bosentan first-line therapy (BREATHE-5 trial)

Portopulmonary Hypertension:

• Definition: PAH in setting of portal hypertension
• Screening: All liver transplant candidates
• Treatment challenges: Drug metabolism altered by hepatic dysfunction
• Liver transplant considerations: mPAP >50 mmHg contraindication

Pregnancy and PAH:

⚠️ CRITICAL: Pregnancy is contraindicated in PAH due to extremely high maternal mortality (17-33%).

Management Principles:

• Contraception: Essential counseling, avoid estrogen-containing methods
• If pregnancy occurs: Multidisciplinary team, early delivery planning
• Safe medications: Sildenafil, inhaled prostacyclins
• Avoid: ERAs (teratogenic), warfarin (teratogenic)

Pediatric PAH:

• Etiology: Higher proportion of IPAH and hereditary PAH
• Drug dosing: Weight-based calculations
• Special considerations: Growth, development, psychosocial support

Genetic Testing in PAH:

Indications for Genetic Testing:

• Family history of PAH or hereditary hemorrhagic telangiectasia
• IPAH diagnosed at age <60 years
• Personal/family history of unexplained sudden cardiac death
• Features suggestive of hereditary PAH syndromes

Common Mutations:

• BMPR2: 70-80% of hereditary PAH cases
• EIF2AK4: Associated with PVOD/PCH
• ACVRL1, ENG: Hereditary hemorrhagic telangiectasia
• KCNK3, CAV1: Rare causes

Emerging Therapies:

Novel Targets Under Investigation:

• Sotatercept: Activin receptor ligand trap, Phase 3 trials ongoing
• Rodatristat ethyl: Tryptophan hydroxylase inhibitor
• Seralutinib: Inhaled PDGFR/CSF1R inhibitor
• Gene therapy: Prostacyclin synthase gene transfer

🔑 KEY CONCEPT: Precision medicine approaches based on genetic profiling and biomarkers represent the future of PAH therapy, moving beyond the current 'one-size-fits-all' approach.

💊 TREATMENT: Recent approval of sotatercept (Winrevair) as add-on therapy for PAH represents the first novel mechanism in over a decade, targeting the activin signaling pathway.